Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis
Abstract Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically p...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Federação Brasileira das Sociedades de Ginecologia e Obstetrícia
2023-08-01
|
| Series: | Revista Brasileira de Ginecologia e Obstetrícia |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032023000600337&tlng=en |
| _version_ | 1797751888723050496 |
|---|---|
| author | Luisa Gracio Ferreira Sartori Bruno Monteiro Nunes Daniela Farah Leticia Maria de Oliveira Claudia Cristina Takano Novoa Marair Gracio Ferreira Sartori Marcelo Cunio Machado Fonseca |
| author_facet | Luisa Gracio Ferreira Sartori Bruno Monteiro Nunes Daniela Farah Leticia Maria de Oliveira Claudia Cristina Takano Novoa Marair Gracio Ferreira Sartori Marcelo Cunio Machado Fonseca |
| author_sort | Luisa Gracio Ferreira Sartori |
| collection | DOAJ |
| description | Abstract Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence. Data Synthesis We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)]. Conclusion Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events. |
| first_indexed | 2024-03-12T16:56:15Z |
| format | Article |
| id | doaj.art-edf3c2434cdd4891a1370bbdd55fc6c1 |
| institution | Directory Open Access Journal |
| issn | 0100-7203 |
| language | English |
| last_indexed | 2024-03-12T16:56:15Z |
| publishDate | 2023-08-01 |
| publisher | Federação Brasileira das Sociedades de Ginecologia e Obstetrícia |
| record_format | Article |
| series | Revista Brasileira de Ginecologia e Obstetrícia |
| spelling | doaj.art-edf3c2434cdd4891a1370bbdd55fc6c12023-08-08T07:41:57ZengFederação Brasileira das Sociedades de Ginecologia e ObstetríciaRevista Brasileira de Ginecologia e Obstetrícia0100-72032023-08-0145633734610.1055/s-0043-1770093Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysisLuisa Gracio Ferreira Sartorihttps://orcid.org/0000-0003-1936-0789Bruno Monteiro Nuneshttps://orcid.org/0000-0003-4343-4661Daniela Farahhttps://orcid.org/0000-0002-9727-9460Leticia Maria de Oliveirahttps://orcid.org/0000-0002-8695-0669Claudia Cristina Takano Novoahttps://orcid.org/0000-0001-5698-0245Marair Gracio Ferreira Sartorihttps://orcid.org/0000-0002-3001-6076Marcelo Cunio Machado Fonsecahttps://orcid.org/0000-0003-0803-3715Abstract Objective To compare the use of mirabegron with anticholinergics drugs for the treatment of overactive bladder (OB). Data Source Systematic searches were conducted in EMBASE, PUBMED, Cochrane, and LILACS databases from inception to September 2021. We included RCTs, women with clinically proven OB symptoms, studies that compared mirabegron to antimuscarinic drugs, and that evaluated the efficacy, safety or adherence. Data Collection RevMan 5.4 was used to combine results across studies. We derived risk ratios (RRs) and mean differences with 95% CIs using a random-effects meta-analytic model. Cochrane Collaboration Tool and GRADE was applied for risk of bias and quality of the evidence. Data Synthesis We included 14 studies with a total of 10,774 patients. Fewer total adverse events was reported in mirabegron group than in antimuscarinics group [RR 0.93 (0.89–0.98)]. The risk of gastrointestinal tract disorders and dry mouth were lower with mirabegron [RR 0,58 (0.48–0.68); 9375 patients; RR 0.44 (0.35–0.56), 9375 patients, respectively]. No difference was reported between mirabegron and antimuscarinics drugs for efficacy. The adherence to treatment was 87.7% in both groups [RR 0.99 (0.98–1.00)]. Conclusion Mirabegron and antimuscarinics have comparable efficacy and adherence rates; however, mirabegron showed fewer total and isolated adverse events.http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032023000600337&tlng=enantimuscarinicsmeta-analysismirabegronoveractive bladder |
| spellingShingle | Luisa Gracio Ferreira Sartori Bruno Monteiro Nunes Daniela Farah Leticia Maria de Oliveira Claudia Cristina Takano Novoa Marair Gracio Ferreira Sartori Marcelo Cunio Machado Fonseca Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis Revista Brasileira de Ginecologia e Obstetrícia antimuscarinics meta-analysis mirabegron overactive bladder |
| title | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
| title_full | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
| title_fullStr | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
| title_full_unstemmed | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
| title_short | Mirabegron and Anticholinergics in the Treatment of Overactive Bladder Syndrome: A Meta-analysis |
| title_sort | mirabegron and anticholinergics in the treatment of overactive bladder syndrome a meta analysis |
| topic | antimuscarinics meta-analysis mirabegron overactive bladder |
| url | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0100-72032023000600337&tlng=en |
| work_keys_str_mv | AT luisagracioferreirasartori mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT brunomonteironunes mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT danielafarah mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT leticiamariadeoliveira mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT claudiacristinatakanonovoa mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT marairgracioferreirasartori mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis AT marcelocuniomachadofonseca mirabegronandanticholinergicsinthetreatmentofoveractivebladdersyndromeametaanalysis |